ENFLONSIA is Merck’s extended half-life monoclonal antibody (mAb) indicated for passive immunization for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in ...

ENFLONSIA is Merck’s extended half-life monoclonal antibody (mAb) indicated for passive immunization for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in ...

ACIP Recommends Use of Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Younger than 8 Months of Age Born ...

HealthDay News — Nirsevimab is effective for reducing the burden of respiratory syncytial virus (RSV) in infants in real-world settings, according to a study published online May 1 in The Lancet ...

THURSDAY, May 8, 2025 (HealthDay News) -- Nirsevimab is effective for reducing the burden of respiratory syncytial virus (RSV) in infants in real-world settings, according to a study published ...

ABILENE, Texas — After multiple dogs contracted the canine pneumovirus, a respiratory virus that contributes to what's commonly known as kennel cough, All Kind Animal Initiative is closing their ...

Learn how environmental air sampling combined with custom microfluidic qPCR panels can be applied for respiratory pathogen surveillance in school settings. Explore the use of microfluidic qPCR for ...

In public health emergencies or in resource-constrained settings, laboratory-based diagnostic methods, such as RT-qPCR, need to be complemented with accurate, rapid, and accessible approaches to ...

About AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) AREXVY contains recombinant RSV glycoprotein F stabilized in the prefusion conformation (RSVPreF3).

AREXVY recommended for adults aged 50-59 at increased risk for severe respiratory syncytial virus (RSV) disease by US Advisory Committee on Immunization Practices Over 13 million adults aged 50-59 ...

A major study presented today at ESCMID Global 2025 has revealed that adults with respiratory syncytial virus-associated acute respiratory infection (RSV-ARI) face a 2.7-fold higher risk of death ...

Chen, L., Han, X., Bai, L. and Zhang, J. (2020) Clinical Characteristics and Outcomes in Adult Patients Hospitalized with Influenza, Respiratory Syncytial Virus and ...